Blood:研究人员正常和恶性造血干细胞的SIRPA敲入模型

2020-04-01 MedSci原创 MedSci原创

人SIRPA敲入小鼠应该是分析人类造血、白血病发生和肿瘤发生的理想基础异种移植模型。

在人-小鼠的异种移植中,信号调节蛋白α(SIRPA)的多态性决定其与人CD47的结合亲和力,对人细胞的植入效率至关重要。

在本研究中,研究人员通过Sirpahuman/human (BRGShuman)建立了一个新的C57BL/6Rag2nullIl2rgnull (BRG) 小鼠品系,该小鼠的Sirpa基因被替整个(8个外显子)换成了人的SIRPA基因。

该小鼠的巨噬细胞对人CD47的亲和力较SirpaNOD/NOD的明显增强,并且没有显示出可检测的针对人类造血干细胞的吞噬作用。

反过来,Sirpahuman/human小鼠的巨噬细胞对小鼠CD47只有中等强度的亲和力,BRGShuman小鼠未表现出在Sirpa-/-小鼠中所见到的血细胞减少症。

在异种移植中,与SirpaNOD / NOD(BRGSNOD)小鼠的BRG相比,BRGShuman小鼠显示出高度有效的移植,可维持人类造血功能,并具有高水平的髓细胞重构,且改善了周围组织的重构。与BRGSNOD小鼠相比,BRGShuman小鼠还显示出急性髓细胞白血病以及皮下移植的人结肠癌细胞的植入和生长显着增强。

综上所述,BRGShuman小鼠或可成为建立更忠实的异种移植模型以研究正常和恶性人类干细胞的有效模型。

原始出处:

Fumiaki Jinnouchi, et al. Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells. Blood. MARCH 23, 2020.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030065, encodeId=7ed32030065aa, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16336, encryptionId=545e16336e2, topicName=SIrP)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Sat Jun 20 21:38:41 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907608, encodeId=2705190e6084d, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Feb 28 05:38:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025422, encodeId=432410254222d, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sat Apr 04 16:38:41 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271509, encodeId=3f8012e15095b, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494721, encodeId=57011494e2155, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047788, encodeId=6462104e788ad, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 01 19:38:41 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
    2020-06-20 passed water
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030065, encodeId=7ed32030065aa, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16336, encryptionId=545e16336e2, topicName=SIrP)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Sat Jun 20 21:38:41 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907608, encodeId=2705190e6084d, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Feb 28 05:38:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025422, encodeId=432410254222d, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sat Apr 04 16:38:41 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271509, encodeId=3f8012e15095b, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494721, encodeId=57011494e2155, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047788, encodeId=6462104e788ad, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 01 19:38:41 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030065, encodeId=7ed32030065aa, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16336, encryptionId=545e16336e2, topicName=SIrP)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Sat Jun 20 21:38:41 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907608, encodeId=2705190e6084d, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Feb 28 05:38:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025422, encodeId=432410254222d, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sat Apr 04 16:38:41 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271509, encodeId=3f8012e15095b, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494721, encodeId=57011494e2155, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047788, encodeId=6462104e788ad, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 01 19:38:41 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
    2020-04-04 独孤立克

    干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2030065, encodeId=7ed32030065aa, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16336, encryptionId=545e16336e2, topicName=SIrP)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Sat Jun 20 21:38:41 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907608, encodeId=2705190e6084d, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Feb 28 05:38:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025422, encodeId=432410254222d, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sat Apr 04 16:38:41 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271509, encodeId=3f8012e15095b, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494721, encodeId=57011494e2155, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047788, encodeId=6462104e788ad, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 01 19:38:41 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2030065, encodeId=7ed32030065aa, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16336, encryptionId=545e16336e2, topicName=SIrP)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Sat Jun 20 21:38:41 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907608, encodeId=2705190e6084d, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Feb 28 05:38:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025422, encodeId=432410254222d, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sat Apr 04 16:38:41 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271509, encodeId=3f8012e15095b, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494721, encodeId=57011494e2155, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047788, encodeId=6462104e788ad, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 01 19:38:41 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
    2020-04-03 俅侠
  6. [GetPortalCommentsPageByObjectIdResponse(id=2030065, encodeId=7ed32030065aa, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16336, encryptionId=545e16336e2, topicName=SIrP)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Sat Jun 20 21:38:41 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907608, encodeId=2705190e6084d, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Feb 28 05:38:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025422, encodeId=432410254222d, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sat Apr 04 16:38:41 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271509, encodeId=3f8012e15095b, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494721, encodeId=57011494e2155, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Apr 03 07:38:41 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047788, encodeId=6462104e788ad, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 01 19:38:41 CST 2020, time=2020-04-01, status=1, ipAttribution=)]
    2020-04-01 CHANGE

    梅斯里提供了很多疾病的模型计算公式,赞一个!

    0

相关资讯

2019 EHA:TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著

第 24 届欧洲血液学协会(EHA)年会上,TG Therapeutics宣布推出TG-1801的临床前数据。TG-1801是一种抗CD47 / CD19的双特异性抗体,可选择性地靶向CD19 + B细胞上的CD47,并阻断成熟B细胞上的CD47-SIRPα介导的'不要吃我'的自我保护信号,来发挥抗肿瘤的作用。

Blood:靶向抑制CD47-SIRPα的治疗活性需要Fc-FcγR的相互作用

CD47抗体,与肿瘤细胞上的CD47结合、阻断其与吞噬细胞上的SIRPα相互作用,在多种癌症中均具有抗肿瘤作用,包括T细胞淋巴瘤(TCL)。近期,研究人员发现细胞表面的CD47在原发性TCLs上的差异性表达,而也可以抑制吞噬作用的I型MHC普遍表达。多种单克隆抗体(mAbs)可阻断CD47-SIRPα相互作用,促进TCL细胞的吞噬作用,靶向I型MHC的抗体一起应用时可增强该作用。在TCL系中,表面

我国首创的抗 PD-1/CD47双特异抗体新药HX009获得NMPA IND批准

梅斯医学小编:国内在原创新药方面速度真快!CD47作为全新的靶点,备受关注。虽然它存在红细胞融解一些严重不良反应,但是,目前通过技术已进行了关键的克服。能进行CD47单抗的研发如就已经不错了。但是作为双特异性靶点,其难度进一步加大,若此双特异性靶点单抗快速上临床,又为中国生物制药开创新的局面! 杭州翰思生物医药有限公司(以下称翰思生物)、武汉翰雄生物技术有限公司宣布,其自主研发的抗 PD

宜明昂科CD20/CD47双抗药物获批进入临床

近日,位于张江科学城的宜明昂科生物医药技术(上海)有限公司(以下简称“宜明昂科”)宣布,公司自主研发的、同时靶向CD47和CD20的双特异性抗体药物(项目编号:IMM0306)获得国家药品监督管理局(NMPA)的临床试验许可(受理号:CXSL1900097)。这是继靶向CD47的IMM01项目获得临床试验研究许可后,宜明昂科第二个进入临床试验研究阶段的项目。

Nature报道:安德森癌症中心重大突破——外泌体还能用于胰腺癌治疗

6月7日Nature在线发表了安德森癌症中心Raghu Kalluri教授新的研究进展:修饰过后的外泌体可以递送iRNA,用于胰腺癌的治疗。外泌体上的CD47避免其被免疫细胞吞噬,在这项研究之前,直接特异性靶向KRAS一直很难做到。生物探索专访过的安德森癌症中心的Raghu Kalluri教授又有了新的研究进展:对于外泌体的遗传操作,可能为胰腺癌提供一种新的治疗方法。相关文章于6月7日在Natur

NEJM:Hu5F9-G4和利妥昔单抗联合阻断非霍奇金淋巴瘤中CD47的疗效评价

由此可见,巨噬细胞检查点抑制剂5F9与利妥昔单抗联合对于具有侵袭性和惰性淋巴瘤的患者表现出了有前景的治疗活性。在该初始研究中未观察到临床上显著的安全性事件。